CPMG Inc
CIK 1372218 · last filed 2024-05-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RETA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 100
DALLAS, TX 75209
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRCT | 10%+ Owner | 2,828,204 | $19.22 | $54.36M | $33.00M | 4 | 2024-05-07 |
| Apollo Endosurgery, Inc. (APEN) Delisted | 10%+ Owner | 0 | $10.00 | $0 | $7.53M | 4 | 2023-04-04 |
| REATA PHARMACEUTICALS INC (RETA) Delisted | Director | 5,577 | $172.36 | $961.3K | $47.62M | 18 | 2020-12-29 |
| GTOP | 10%+ Owner | 7,889,947 | $47.25 | $372.80M | $11.28M | 4 | 2007-06-13 |
Recent Filings · Page 3 of 4
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-08-18 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +308,220 | $5.27M | EDGAR |
| 2016-08-09 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +802,000 | $8.82M | EDGAR |
| 2016-06-30 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +164,600 | $3.26M | EDGAR |
| 2016-06-28 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +73,403 | $1.41M | EDGAR |
| 2016-06-08 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +24,220 | $425.6K | EDGAR |
| 2016-06-03 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +8,035 | $107.8K | EDGAR |
| 2016-06-01 | REATA PHARMACEUTICALS INC (RETA) Delisted | Mixed | +362,522 | $3.19M | EDGAR |
| 2008-12-12 | — | Sell (S) | −8,125,370 | $0 | |
| 2007-06-13 | GTOP | Other (J) | — | $0 | EDGAR |
| 2007-05-24 | GTOP | Buy (P) | +437,416 | $1.58M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.